Wednesday, November 08, 2017 10:15:31 AM
We need to file our 10Q next week. After that, we can announce our ‘go-forward’ plans for the company. This includes: the ongoing infomercial campaign for Pet Pain-Away; the marketing of Nyloxin; the retail rollout for Nyloxin; the ongoing efforts to get our products into the VA and government buyers; our efforts in International registrations for our products; and our efforts in moving RPI-78M into clinical trials for Pediatric Multiple Sclerosis under our Orphan Designation.
We are working with finance partners and potential joint venture partners to bring in from $2M to $20M in furtherance of the business plan. We expect to make announcements later this month to update our shareholders.
Thank you for your interest in Nutra Pharma,
Rik
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM